『Hormones, Menopause, and the Cost of Saying No』のカバーアート

Hormones, Menopause, and the Cost of Saying No

Hormones, Menopause, and the Cost of Saying No

無料で聴く

ポッドキャストの詳細を見る
Dr. Jenn Simmons is joined by Dr. Louise Newson, a hormone-focused physician and menopause educator, for a wide-ranging conversation about the difference between bioidentical and synthetic hormones, why hormone fear persists in medicine, and how that fear affects women’s long-term health. They also dig into breast cancer, BRCA mutations, perimenopause, testosterone, compounding, and why shared decision-making matters more than blanket rules.Key topicsDr. Louise Newson shares how her medical path moved from internal medicine and pathology into general practice, medical writing, and ultimately menopause and hormone care.She explains why the Women’s Health Initiative and other early studies created lasting confusion by mixing synthetic hormones with bioidentical hormones.Dr. Newson breaks down the biological difference between endogenous hormones and synthetic compounds, using receptor biology and chemical structure to show why they are not interchangeable.The conversation examines why many clinicians still fear hormone therapy, including outdated warnings, guideline dependence, pharma influence, and professional ego.Dr. Newson argues that menopause is not just a “natural transition” but a hormone deficiency with real biological consequences, especially for bone, cardiovascular, brain, and metabolic health.They discuss the misconception that hormones should only be used briefly, and why some women benefit from continuing treatment based on symptoms, quality of life, and future risk reduction.The episode covers testosterone in women, including why it is underused, why it is often misunderstood as only a libido hormone, and how it can affect mood, energy, sleep, joints, and cognition.They explore how perimenopause is best approached by assessing progesterone, estradiol, and testosterone separately rather than relying on one broad label.Dr. Newson addresses compounding, explaining why individualized preparations can be useful and why “compounded” does not automatically mean unsafe.The discussion moves into breast cancer and BRCA mutations, with a focus on why hormone decisions should be individualized rather than ruled out by category.They emphasize that women need better information to make informed choices, and that refusing to offer hormone treatment can itself cause harm.Timestamps00:00 - Why Dr. Louise Newson is such a trusted voice on hormones01:17 - Losing her father young and the path into medicine03:39 - From prescribing HRT to becoming a medical writer04:04 - The WHI study and why it changed everything05:55 - Why antidepressants were replacing hormone care07:32 - Synthetic hormones versus bioidentical hormones09:33 - How receptor biology explains the difference10:32 - Chemical examples that show how small changes matter11:30 - Why WHO classified ethinyl estradiol as carcinogenic13:34 - Why warnings and guidelines keep the fear alive15:28 - The vacuum created when doctors stopped learning hormones16:41 - Training more than 33,000 clinicians in menopause care18:57 - Why gynecologists are not necessarily hormone experts19:24 - Why endocrinology and psychiatry often miss the issue20:49 - Is menopause a disease or a normal transition?22:15 - Why early menopause raises the stakes23:34 - Why hormone therapy should remain a choice24:27 - What happens when the body adapts to low hormones25:41 - Why supplements cannot replace estradiol, progesterone, or testosterone28:55 - What older women discover when they finally try hormones29:57 - The so-called window of opportunity after age 6031:31 - Why hormones may still help women with heart disease33:41 - Why there will never be a big randomized trial35:07 - Why medicine accepts some evidence standards and ignores others37:39 - The compounding controversy and why it makes no sense39:36 - Why testosterone can be safer as a pump or customized preparation40:03 - Why Dr. Newson dislikes the words menopause and perimenopause40:59 - Treating progesterone, estradiol, and testosterone separately42:38 - Why testosterone is so misunderstood in women44:03 - The limits of libido-only thinking45:28 - Testosterone data in men and why it gets ignored for women46:11 - BRCA mutations, ovarian cancer, and hormone eligibility48:56 - Why society guidelines are not the same as facts49:54 - The hidden harm of withholding hormones51:52 - The woman whose life changed after starting treatment53:09 - Why not prescribing can create real long-term danger54:11 - Women often know more than their providers now55:38 - The breast cancer population and refusing tamoxifen or aromatase inhibitors56:46 - Estrogen receptor positive does not mean estrogen caused the cancer60:06 - Risks of tamoxifen and aromatase inhibitors61:33 - Testosterone use after breast cancer63:05 - Why cancer and recurrence happen with or without hormones65:26 - Who Dr. Newson would refuse to treat66:55 - A breast cancer case where hormones supported mental health68:09 - Why old breast cancer treatments included ...
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません